27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Delirium was associated with a higher risk of nursing home admission in participants without dementia (SHR 1.23, 95% CI 1.14-1.34) and with pre-existing dementia (SHR 1.22, 95% CI 1.07-1.38). 5 key findings →
Design: cohort study Participants: 13 Evidence: moderate
Full summary, score breakdown and related studies → Original source
During the study period, 82,118 patients with dementia (mean (SD) age, 83.04 (10.04), 51,170 (62.21%) female) underwent an acute hospitalization, of which 41,227 (50.27%) received care in hospitals that implemented a palliative care program. 4 key findings →
Design: cohort study Participants: 82,118 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The sample included 673,102 PWD (mean age 86, 66% female, 85% White, 7.3% Black, 6.3% Hispanic, 1.6% AAPI) enrolled in 4371 hospices nationwide. 5 key findings →
Design: cohort study Participants: 673,102 Evidence: moderate
Full summary, score breakdown and related studies → Original source
ACP billing codes from 6 months before to 6 months after admission for inpatient surgery. 5 key findings →
Design: cohort study Participants: 289,428 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Dementia was diagnosed at a mean of 5.1 ± 3.4 years post-KTx. 5 key findings →
Design: cohort study Participants: 3,285 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Between Feb 24, 2021, and March 5, 2023, 377 dyads were randomly assigned (1:1), 189 to usual treatment and 188 to intervention. 2 key findings →
Design: RCT Participants: 377 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Exercise intensity did not differentially affect cognitive trajectory. 2 key findings →
Design: phase-3-trial Participants: 296 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
These findings extend the evidence base for multidomain lifestyle interventions to populations historically under-represented in dementia research, supporting their feasibility and scalability as strategies to reduce cognitive decline risk amid the rapidly growing burden of dementia in low-income and middle-income countries. 3 key findings →
Design: RCT Participants: 1,065 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We aimed to determine the effect of live attenuated herpes zoster vaccination on incident dementia diagnoses among people aged 70 years and older using a natural experiment in Ontario, Canada, and to triangulate these findings, using a second natural experiment in Ontario and a quasi-experimental approach that uses data from multiple Canadian provinces. 3 key findings →
Design: cohort Participants: 232,124 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In this study, several factors, mostly modifiable, were associated with a higher risk of YOD. 4 key findings →
Design: cohort Participants: 356,052 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The study findings suggest delirium was a strong risk factor for death and incident dementia among older adult patients. 3 key findings →
Design: cohort Participants: 110,422 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A higher percentage of daily energy consumption of ultraprocessed foods was associated with cognitive decline among adults from an ethnically diverse sample. 5 key findings →
Design: cohort Participants: 10,775 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
High UPF consumption is associated with dementia. 4 key findings →
Design: meta-analysis Participants: 867,316 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
4024 articles were identified, and 74 were included in our narrative synthesis. 2 key findings →
Design: meta-analysis Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of the 120 participants (mean age, 71.4 [SD, 8.6] years; 55% were female), 93 (77.5%) completed the trial. 1 key finding →
Design: phase-2-trial Participants: 120 Evidence: null result
Full summary, score breakdown and related studies → Original source Free full text
In this prospective cohort study, we included adults aged 40 years or older with subjective cognitive decline, mild cognitive impairment, or dementia, based on cognitive test results and clinical assessments, consecutively recruited at two memory clinics in Sweden, as part of the Swedish BioFINDER-2 study. 3 key findings →
Design: cohort Participants: 572 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Clinical data supported a delayed onset of cognitive impairment in persons who were heterozygous for the APOE3 Ch variant in a kindred with a high prevalence of autosomal dominant Alzheimer's disease. 3 key findings →
Design: cohort Participants: 1,077 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The risk of developing Alzheimer's disease (AD) significantly increases in individuals carrying the APOEε4 allele. 5 key findings →
Design: case-control Participants: 7,185 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Participants had a mean (SD) age of 66.9 (9.9) years; 971 (33.3%) were Aβ positive by either CSF or PET, 1667 (57.2%) were women, and 1108 (38.1%) carried at least 1 APOE ε4 allele. 5 key findings →
Design: cross-sectional Participants: 2,916 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Circulating NfL and GFAP may, independently and jointly, provide useful clinical insight regarding dementia risk and prognosis. 4 key findings →
Design: cohort Participants: 1,712 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The mean age was 74.2 years (SD, 8.3 years), 48% were women, 23% had subjective cognitive decline, 44% had mild cognitive impairment, and 33% had dementia. 2 key findings →
Participants: 307 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The best CSF measures for identifying MCI-AD were Aβ42/total tau (t-tau) and Aβ42/hyperphosphorylated tau (p-tau) (area under the curve [AUC] 0.93-0.94). 3 key findings →
Design: longitudinal study Participants: 122 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among the 1453 participants in the Framingham dementia study sample, the mean (SD) age was 75 (7) years; 792 (54.5%) were female. 3 key findings →
Design: cohort study Participants: 1,453 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of 343 participants, the mean (SD) age was 72.56 (7.24) years, and 157 (51.1%) were female. 1 key finding →
Design: cohort study Participants: 343 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In response to sleep loss (+17.2%), compared with normal sleep (+1.8%), the evening to morning ratio was increased for t-tau ( p = 0.035). 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →